États-Unis - anglais - NLM (National Library of Medicine)

remedyrepack inc. - insulin aspart (unii: d933668qvx) (insulin aspart - unii:d933668qvx) - insulin aspart is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. insulin aspart is contraindicated: - during episodes of hypoglycemia [see warnings and precautions ( 5.3)] - in patients with hypersensitivity to insulin aspart or one of its excipients, [see warnings and precautions ( 5.5)] risk summary available information from published randomized controlled trials with insulin aspart use during the second trimester of pregnancy have not reported an association with insulin aspart and major birth defects or adverse maternal or fetal outcomes [see data] . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see clinical considerations] . in animal reproduction studies, administration of subcutaneous insulin aspart to pregnant rats and rabbits during the period of organogenesis did not cause adverse developmental effects at exposures 8-times and equal to the human subcutaneous dose of 1 unit/kg/day, respectively. pre- and post-implantation losses and visceral/skeletal abnormalities were seen at higher exposures, which are considered secondary to maternal hypoglycemia. these effects were similar to those observed in rats administered regular human insulin [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes with a periconceptional hba 1c >7% and has been reported to be as high as 20 to 25% in women with a periconceptional hba 1c >10%. the estimated background risk of miscarriage for the indicated population is unknown. clinical considerations disease-associated maternal and/or embryo-fetal risk poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. data human data published data from 5 randomized controlled trials of 441 pregnant women with diabetes mellitus treated with insulin aspart during the late 2 nd trimester of pregnancy did not identify an association of insulin aspart with major birth defects or adverse maternal or fetal outcomes. however, these studies cannot definitely establish the absence of any risk because of methodological limitations, including a variable duration of treatment and small size of the majority of the trials. animal data fertility, embryo-fetal and pre- and postnatal development studies have been performed with insulin aspart and regular human insulin in rats and rabbits. in a combined fertility and embryo-fetal development study in rats, insulin aspart was administered before mating, during mating, and throughout pregnancy. further, in a pre- and postnatal development study insulin aspart was given throughout pregnancy and during lactation to rats. in an embryo-fetal development study insulin aspart was given to female rabbits during organogenesis. the effects of insulin aspart did not differ from those observed with subcutaneous regular human insulin. insulin aspart, like human insulin, caused pre- and post-implantation losses and visceral/skeletal abnormalities in rats at a dose of 200 units/kg/day (approximately 32 times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents) and in rabbits at a dose of 10 units/kg/day (approximately three times the human subcutaneous dose of 1 unit/kg/day, based on human exposure equivalents). no significant effects were observed in rats at a dose of 50 units/kg/day and in rabbits at a dose of 3 units/kg/day. these doses are approximately 8 times the human subcutaneous dose of 1 unit/kg/day for rats and equal to the human subcutaneous dose of 1 unit/kg/day for rabbits, based on human exposure equivalents. the effects are considered secondary to maternal hypoglycemia. risk summary there are no data on the presence of insulin aspart in human milk, the effects on the breastfed infant, or the effect on milk production. one small published study reported that exogenous insulin, including insulin aspart, was present in human milk. however, there is insufficient information to determine the effects of insulin aspart on the breastfed infant. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for insulin aspart, and any potential adverse effects on the breastfed infant from insulin aspart, or from the underlying maternal condition. the safety and effectiveness of insulin aspart to improve glycemic control have been established in pediatric patients with diabetes mellitus. use of insulin aspart for this indication is supported by evidence from an adequate and well-controlled study in 283 pediatric patients with type 1 diabetes mellitus aged 6 to 18 years and from studies in adults with diabetes mellitus [see adverse reactions ( 6.1), clinical pharmacology ( 12.3), and clinical studies ( 14)] . of the total number of patients (n=1,375) treated with insulin aspart in 3 controlled clinical studies, 2.6% (n=36) were 65 years of age or over. one-half of these patients had type 1 diabetes (18/1285) and the other half had type 2 diabetes (18/90). the hba 1c response to insulin aspart, as compared to regular human insulin, did not differ by age. patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent insulin aspart dose adjustment and more frequent blood glucose monitoring [see warnings and precautions ( 5.3) and clinical pharmacology ( 12.3)]. patients with hepatic impairment may be at increased risk of hypoglycemia and may require more frequent insulin aspart dose adjustment and more frequent blood glucose monitoring [see warnings and precautions ( 5.3) and clinical pharmacology ( 12.3)].

États-Unis - anglais - NLM (National Library of Medicine)

novo nordisk pharma, inc. - insulin degludec (unii: 54q18076qb) (insulin degludec - unii:54q18076qb) - insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. limitations of use insulin degludec is contraindicated: risk summary available data from one unpublished trial and the published literature with insulin degludec use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in a randomized, parallel-group, open-label actively controlled clinical trial that included 91 pregnant women with type 1 diabetes who were administered insulin degludec once daily and insulin aspart, beginning in gestational weeks 8 to 13 or prior to conception, no clear evidence of maternal or fetal risk associated with insulin degludec use was observed (see data ). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). rats and rabbits were exposed to insulin degludec in animal reproduction studies during organogene

Philippines - anglais - FDA (Food And Drug Administration)

novo nordisk pharmaceuticals (philippines), inc.; distributor: novo nordisk pharmaceuticals (philippines), inc. - insulin human - suspension for injection (sc) - 100 iu/ml (soluble insulin 30% and isophane insulin 70%)

Philippines - anglais - FDA (Food And Drug Administration)

pnf pharmaceutical, inc.; distributor: multicare pharmaceuticals phils. inc. - insulin human (rdna) - suspension for injection (im/sc) - 100 iu/ml (100% isophane insulin human)

Philippines - anglais - FDA (Food And Drug Administration)

n/a; importer: novo nordisk pharmaceuticals (philippines), inc.; distributor: n/a - insulin human (rdna) - solution for injection (sc) - 100 iu/ml (70% isophane + 30% soluble insulin human)

Philippines - anglais - FDA (Food And Drug Administration)

pnf pharmaceutical, inc.; distributor: duopharma trade phils., inc. - insulin human (rdna) - suspension for injection (im/sc) - 100 iu/ml (100% isophane insulin human)

Philippines - anglais - FDA (Food And Drug Administration)

n/a; importer: pnf pharmaceutical, inc; distributor: jackpharma inc - insulin human (rdna) - suspension for injection (im/sc) (100% isophane insulin human) - 100 iu/ml

Philippines - anglais - FDA (Food And Drug Administration)

n/a; importer: pnf pharmaceutical, inc; distributor: mega lifesciences limited inc - insulin human (rdna) - suspension for injection (im/sc) (100% isophane insulin human) - 100 iu/ml

Israël - anglais - Ministry of Health

eli lilly israel ltd - insulin lispro; insulin lispro protamine - suspension for injection - insulin lispro 50 %; insulin lispro protamine 50 % - insulin lispro - insulin lispro - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

États-Unis - anglais - NLM (National Library of Medicine)

biocon biologics inc. - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine-yfgn is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. limitations of use insulin glargine-yfgn is not recommended for the treatment of diabetic ketoacidosis. insulin glargine-yfgn is contraindicated: risk summary published studies with use of insulin glargine products during pregnancy have not reported a clear association with insulin glargine products and adverse developmental outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dosage of 0.2 units/kg/day. overall, the effects of insulin glargine did not generally differ from those observed with regular human insulin (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically r